Efficacy of Osimertinib in Patients With Lung Cancer

Advanced Non-Small Cell Lung Cancer Clinical Trial

Official title:

Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06174857
• Other study ID #: EGFR 19 delins
• Status: Recruiting
• Start date: January 1, 2021
• Est. completion date: September 15, 2025

Study information

• Verified date: December 2023
• Source: Hunan Province Tumor Hospital
• Contact: Yongchang C Zhang, MD
• Phone: +8613873123436
• Email: zhangyongchang[@]csu.edu.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 15, 2025
• Est. primary completion date: June 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be =18 years.

• Provision of fully informed consent prior to any study specific procedures.

• Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.

• According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Advanced Non-Small Cell Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
China	Hunan Cancer hospital	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Hunan Province Tumor Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression-free survival	From registration onto that step until death, or censored at the date of last contact.	3 years
Primary	Overall survival	From registration onto that step until death, or censored at the date of last contact.	3 years